Loading
Radiation oncologist behind the MACH-NC meta-analyses that proved chemoradiotherapy helps head and neck cancer, and the first FLASH-treated patient.
Jean Bourhis led the MACH-NC individual patient data meta-analyses showing that concomitant chemotherapy adds about 6.5% absolute survival to radiotherapy in head and neck cancer, and the MARCH meta-analysis of altered fractionation, both of which set global standards. He treated the first patient with FLASH radiotherapy in 2018 and leads the clinical FLASH programme at CHUV.
| Title | Journal | Year |
|---|---|---|
| Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients | Radiotherapy and Oncology | 2009 |
| Treatment of a first patient with FLASH-radiotherapy | Radiotherapy and Oncology | 2019 |
Shares Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne, FLASH radiotherapy and the tags radiotherapy, flash.
Shares Head and neck squamous cell carcinoma, IMRT / IGRT (modern external beam) and the tags head-and-neck, radiotherapy.
Shares Radiotherapy and Oncology, Head and neck squamous cell carcinoma and the tag radiotherapy.
Shares Head and neck squamous cell carcinoma, IMRT / IGRT (modern external beam) and the tag head-and-neck.
Shares NIVOPOSTOP (GORTEC 2018-01), Head and neck squamous cell carcinoma.
Shares IMRT / IGRT (modern external beam) and the tag radiotherapy.
Shares NIVOPOSTOP (GORTEC 2018-01), IMRT / IGRT (modern external beam) and the tag head-and-neck.
Shares NIVOPOSTOP (GORTEC 2018-01), IMRT / IGRT (modern external beam) and the tag head-and-neck.